{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:16:15Z","timestamp":1791404175235,"version":"4.3.3"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3517,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To determine population pharmacokinetic parameters of pyrazinamide after multiple oral doses given to children and adults with tuberculosis.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Prospective, multiple\u2010dose population pharmacokinetic study.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Five hospitals in the United States.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> Sixty\u2010seven adults and 23 children with active tuberculosis.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> The 90 patients received multiple oral doses of pyrazinamide as part of their treatment, based on the best clinical judgment of the attending physicians and in keeping with standard clinical practices at each institution. The patients also received other antituberculosis drugs empirically or based on in vitro susceptibility data.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> Serum samples were collected over 12 hours after dosing and were assayed with a validated gas chromatography assay with mass selective detection. Concentration\u2010time data were analyzed by using population methods. Pyrazinamide concentrations increased linearly with increasing oral doses (185\u20133550 mg). Median maximum serum concentration values were 41.0 \u03bcg\/ml with daily dosing and 66.1 \u03bcg\/ml with larger, twice\u2010weekly dosing. Incomplete (18%) or delayed (30%) absorption was more common in children than in adults (1% for each). Pharmacokinetic parameters of pyrazinamide were independent of human immunodeficiency virus status and patient demographics, except for body weight. Population elimination half\u2010life values in pediatric and adult patients were 3.5 and 6.0 hours, respectively. Median volume of distribution (L\/kg) was 32% larger in children, and median clearance (L\/hr\/kg) was 106% larger in children, with a resultant median half\u2010life 43% shorter in children.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Pyrazinamide concentrations and most pharmacokinetic parameters were comparable to those previously published. Apparent half\u2010life was somewhat shorter than that in previous reports. Compared with adults, absorption of pyrazinamide in children appeared more likely to be incomplete or delayed.<\/jats:p>","DOI":"10.1592\/phco.22.9.686.34067","type":"journal-article","created":{"date-parts":[[2004,6,7]],"date-time":"2004-06-07T04:48:04Z","timestamp":1086583684000},"page":"686-695","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Population Pharmacokinetic Modeling of Pyrazinamide in Children and Adults with Tuberculosis"],"prefix":"10.1002","volume":"22","author":[{"given":"Min","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Starke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry Jean","family":"Stambaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Bulpitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun E.","family":"Berning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(84)90024-2"},{"key":"e_1_2_1_3_2","first-page":"510","article-title":"Pharmaco\u2010kinetic studies on antituberculosis regimens in human. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short\u2010course regimens: single administration study","volume":"132","author":"Acocella G.","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2670"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03138.x"},{"key":"e_1_2_1_6_2","first-page":"119","article-title":"Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics","volume":"3","author":"Gurumurthy P.","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"e_1_2_1_8_2","volume-title":"User manual for version 10.7 USC*PACK collection of PC programs","author":"Jelliffe R.W.","year":"1995"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200006000-00019"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"10","author":"Cockcroft D.W.","year":"1976","journal-title":"Nephron"},{"key":"e_1_2_1_11_2","volume-title":"WinNonlin version 3.0: examples guide","author":"Pharsight Corporation.","year":"1998"},{"key":"e_1_2_1_12_2","first-page":"668","volume-title":"Antimicrobial therapy and vaccines","author":"Heifets L.B.","year":"1999"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199708000-00006"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<37::AID-PPUL8>3.0.CO;2-G"},{"key":"e_1_2_1_15_2","first-page":"551","article-title":"The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide","volume":"13","author":"Walubos A.","year":"1991","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_1_16_2","first-page":"65","article-title":"Serum pharmaco\u2010kinetics of antimycobacterial drugs in patients with multidrug\u2010resistant tuberculosis during therapy","volume":"3","author":"Yew W.W.","year":"1999","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_1_17_2","first-page":"133","article-title":"Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis","volume":"3","author":"Roy V.","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502023320518"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000901"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-4-199708150-00006"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/514513"},{"key":"e_1_2_1_22_2","first-page":"319","article-title":"Pyrazinamide\u2010isoniazid in tuberculosis","volume":"69","author":"McDermott W.","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"e_1_2_1_23_2","first-page":"371","article-title":"Hepatic toxicity of pyrazinamide used with isoniazid in tuberculosis patients","volume":"80","author":"Mount F.W.","year":"1959","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(69)90017-8"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.22.9.686.34067","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.22.9.686.34067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:37:48Z","timestamp":1761053868000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.22.9.686.34067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1592\/phco.22.9.686.34067"],"URL":"https:\/\/doi.org\/10.1592\/phco.22.9.686.34067","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}